Introduction
============

Cryptophycins are macrocyclic depsipeptides, which show very high cytotoxicity even against multidrug-resistant cell lines. They inhibit mitosis of eukaryotic cells by interacting with the β-subunit of α/β-tubulin heterodimers. Numerous natural and artificial analogs have been analysed in structure--activity relationship (SAR) studies. The unit B of cryptophycins contains a considerably modified D-tyrosine derivative ([Fig. 1](#F1){ref-type="fig"}). Substituent variations at unit B are not well tolerated. Both the methoxy and the chloro substituent are required for full biological activity \[[@R1]--[@R4]\].

![The four building blocks (units) A--D of cryptophycin-1 (**1**) and cryptophycin-52 (**2**).](Beilstein_J_Org_Chem-07-243-02){#F1}

The previously published synthetic route to unit B precursor **4** involves a three-step modification of D-tyrosine by chlorination, protecting group introduction and double methylation followed by a final saponification reaction to give carboxylic acid **5** ([Scheme 1](#C1){ref-type="fig"}). A number of experimental procedures for this route have been published \[[@R5]--[@R7]\]. The selective monochlorination of D-tyrosine is quite cumbersome since the formation of the dichlorinated product must be minimized and the presence of unreacted D-tyrosine after the reaction must be completely avoided. The dichlorinated by-product has to be separated by column chromatography when purifying the desired methyl ester **4** \[[@R7]--[@R8]\]. In addition, another major drawback of this synthetic route is the use of highly toxic and carcinogenic dimethyl sulfate.

![Synthesis of the unit B precursor from D-tyrosine (**3**). Reagents and conditions \[[@R7]\]: a) SO~2~Cl~2~, AcOH, rt, 90 min, (75%); b) Boc~2~O, NaOH, *t*-BuOH/H~2~O, rt, 16 h (quant.) c) Me~2~SO~4~, K~2~CO~3~, acetone, reflux, 4 h (99%); d) LiOH, H~2~O/THF/MeOH, rt, 1 h (93%).](Beilstein_J_Org_Chem-07-243-03){#C1}

A completely different route to unit B precursor **8** ([Scheme 2](#C2){ref-type="fig"}) is based on a phase transfer catalyst (PTC) mediated asymmetric alkylation. However, the required cinchonine derived chiral catalyst is not commercially available \[[@R9]\].

![Unit B synthesis by a chiral PTC approach. Reagents and conditions \[[@R9]\]: a) *N*-(Diphenylmethylene)glycine *tert*-butyl ester, 50% KOH, toluene/CHCl~3~, chiral phase transfer catalyst (0.01 equiv), 0 °C, 20 h (87%; 96% *ee*); b) 15% citric acid, THF, rt, 16 h; c) FmocCl, Na~2~CO~3~, THF, rt, 14 h, (72% over two steps).](Beilstein_J_Org_Chem-07-243-04){#C2}

Results and Discussion
======================

We envisaged a two step synthesis for the unit B precursor **4** ([Scheme 1](#C1){ref-type="fig"}) from commercially available non-toxic starting materials based on an asymmetric hydrogenation approach to make the unit B precursor synthesis shorter and safer. In general, there is also a whole variety of possible stereoselective synthetic methods available to synthesize modified α-amino acids, such as the classical Schöllkopf-method \[[@R10]\] or catalytic approaches \[[@R11]--[@R12]\]. The unit B precursor of cryptophycin is a phenylalanine derivative. An asymmetric hydrogenation approach for the synthesis of such α-amino acids is well-established \[[@R12]\]. In the first step of the developed synthesis 3-chloro-4-methoxybenzaldehyde is reacted with *rac*-Boc-α-phosphonoglycine trimethyl ester (**9**) \[[@R13]--[@R14]\] to yield olefin **10** in a completely *Z*-selective Horner--Wadsworth--Emmons (HWE) reaction ([Scheme 3](#C3){ref-type="fig"}). Asymmetric hydrogenation using the commercially available \[(COD)Rh-(*R*,*R*)-Et-DuPhos\]BF~4~ catalyst \[[@R14]--[@R15]\] gave the anticipated methyl ester **4** ([Scheme 1](#C1){ref-type="fig"}) in 97% yield with an *ee* exceeding 98% (determined by chiral HPLC). Hydrogenation of **10** with 10% Pd/C was envisaged to obtain ***rac***-**4** as a reference for the determination of the *ee*. Interestingly, due to this more reactive catalyst a complete reductive dehalogenation was observed to give *rac*-Boc-Tyr(Me)-OMe (***rac*** **-11**) as reported for a similar case \[[@R16]\]. Therefore, ***ent***-**4** was synthesized analogously also using the commercially available enantiomeric catalyst (\[(COD)Rh-(*S*,*S*)-Et-DuPhos\]BF~4~).

![Unit B precursor **4** synthesis by asymmetric hydrogenation. Reagents and conditions: a) 3-Chloro-4-methoxybenzaldehyde, 1,1,3,3-tetramethylguanidine, CH~2~Cl~2~, 0 °C to rt, 16 h (84%); b) \[(COD)Rh-(*R*,*R*)-Et-DuPhos\]BF~4~ (1.9 mol %), H~2~, dry and degassed MeOH, 3--6 bar, 21.5 h (97%; 98% *ee*); c) 10% Pd/C, H~2~, MeOH, 16 h, (76%).](Beilstein_J_Org_Chem-07-243-05){#C3}

Conclusion
==========

A novel two step synthesis of the important cryptophycin unit B precursor **4** is disclosed based on a HWE reaction followed by a highly enantioselective \[(COD)Rh-(*R*,*R*)-Et-DuPhos\]BF~4~ mediated asymmetric hydrogenation. This high-yielding access is more convenient and avoids hazardous chemicals in contrast to the established method.

Supporting Information
======================

###### 

Full experimental procedures and detailed analytical data for the synthesis of **10** and **4** including chiral HPLC spectra.
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